Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. ABBV
4. DFTX
5. CART
6. HIVE
7. RGNX
8. MPLT
9. INTC
10. ELDN

Go back to Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DL

AbbVie (ABBV) Falls Following Q3 Release - Softness in US Sales Likely to 'Raise Concerns'

October 28, 2022 9:53 AM EDT

AbbVie (NYSE: ABBV) shares are down more than 5% in early Friday trading after the company reported third-quarter earnings before the open, missing revenue expectations.

The company reported earnings of $3.66 per share, $0.08 better than the analyst estimate of $3.58, while revenue for the quarter came in at $14.81 billion versus the consensus estimate of $14.93 billion.

Following the report, Mizuho Securities analyst Uy Ear told investors in a note... More